At a glance
- Originator NAEJA Pharmaceutical
- Class Beta-lactams; Cytostatic antibiotics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 17 Oct 2001 Discontinued-Preclinical for Cancer in Canada (Unknown route)
- 21 May 2001 No-Development-Reported for Cancer in Canada (Unknown route)
- 26 Sep 1996 Preclinical development for Cancer in Canada (Unknown route)